 P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities DLTs, cytokine release syndrome CRS, graft vs host disease GVHD or immune effector cell-associated neurotoxicity syndrome ICANS P-MUC1C-ALLO1 demonstrated encouraging clinical activity including an objective partial response in a breast cancer patient at the lowest dose P-BCMA-ALLO1 demonstrated responses in heavily pre-treated patients with relapsedrefractory multiple myeloma at the lowest CAR-T dose tested including in patients who had failed prior BCMA-targeted therapy and patients with high-risk disease SAN DIEGO , Dec. 6, 2022 PRNewswire -- Poseida Therapeutics, Inc. Nasdaq: PSTX, a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced it will present early clinical results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the European Society for Medical Oncology Immuno-Oncology ESMO I-O 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022. These early data being presented at ESMO I-O for our first two fully allogeneic programs reinforce our belief that our technology and approach have the potential to deliver differentiated off-the-shelf CAR-T cell therapies to patients fighting cancer, said Mark Gergen, Chief Executive Officer of Poseida Therapeutics. 